Sinovac Biotech Ltd (NASDAQ:SVA) a leading biopharmaceutical company in China has reported its fourth quarter and full year unaudited results for the period ending December 31, 2013. Sinovac Biotech Ltd. (NASDAQ:SVA) stock performance was 17.13% in last session and finished the day at $8.07. Traded volume was 4,876,818 million shares in the last session and the average volume of the stock remained 342.45 million shares. The beta of the stock remained 1.30. Sinovac Biotech Ltd. (NASDAQ:SVA) insider ownership is 30.46%.

Neuralstem, Inc. (NYSEMKT:CUR) on Mar. 17 announced that the final results from the Phase I safety trial using NSI-566 spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) were published in the peer-reviewed journal, “Annals of Neurology”. Neuralstem, Inc. (NYSEMKT:CUR) rose 12.17 percent to $4.61 yesterday on volume of 2.33 million shares. The intra-day range of the stock was $3.95 to $4.75. Neuralstem, Inc. (NYSEMKT:CUR) has a market capitalization of $397.47 million.

Equities researchers at Barclays began coverage on shares of Durata Therapeutics (NASDAQ:DRTX) in a research report issued to clients and investors on Tuesday, American Banking News reports. The firm set a “buy” rating and a $13.91 price target on the stock. Barclays’ target price would suggest a potential downside of 16.46% from the stock’s previous close. Durata Therapeutics Inc (NASDAQ:DRTX)’s stock on Mar20, 2014 reported a decrease of -6.97% to the closing price of $15.49. Its fifty two weeks range is $6.65 -$16.99. The total market capitalization recorded $412.66 million. The overall volume in the last trading session was 577,738 million shares. In its share capital, Durata Therapeutics Inc (NASDAQ:DRTX) has 26.62 million outstanding shares.

Recro Pharma, Inc (NASDAQ:REPH) a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for post-operative pain, today announced the appointments of Alfred F. Altomari and Dr. Michael Berelowitz to the Company’s Board of Directors. On Thursday, shares of Recro Pharma Inc (NASDAQ:REPH) advanced 7.77% to close the day at $9.15.